1. Home
  2. HTGC vs ARQT Comparison

HTGC vs ARQT Comparison

Compare HTGC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hercules Capital Inc.

HTGC

Hercules Capital Inc.

HOLD

Current Price

$15.59

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$21.51

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTGC
ARQT
Founded
2003
2016
Country
United States
United States
Employees
50
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HTGC
ARQT
Price
$15.59
$21.51
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$18.86
$34.00
AVG Volume (30 Days)
1.8M
2.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
12.13%
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
N/A
$376,072,000.00
Revenue This Year
$11.18
$34.85
Revenue Next Year
$5.24
$29.39
P/E Ratio
$8.61
N/A
Revenue Growth
N/A
91.34
52 Week Low
$13.70
$12.72
52 Week High
$19.67
$31.77

Technical Indicators

Market Signals
Indicator
HTGC
ARQT
Relative Strength Index (RSI) 49.70 47.22
Support Level $15.22 $21.12
Resistance Level $15.96 $21.84
Average True Range (ATR) 0.31 0.99
MACD -0.05 0.13
Stochastic Oscillator 40.12 67.04

Price Performance

Historical Comparison
HTGC
ARQT

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: